Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients

View ORCID ProfileJessica Bassi, View ORCID ProfileOlivier Giannini, Chiara Silacci-Fregni, Laura Pertusini, Paolo Hitz, Tatiana Terrot, Yves Franzosi, Francesco Muoio, Christian Saliba, Marcel Meury, Exequiel A. Dellota Jr., Josh Dillen, Patrick Hernandez, View ORCID ProfileNadine Czudnochowski, Elisabetta Cameroni, Nicola Beria, Mariangela Ventresca, Alberto Badellino, Soraya Lavorato-Hadjeres, Elisabetta Lecchi, Tecla Bonora, Matteo Mattiolo, Guido Trinci, Daniela Garzoni, Giuseppe Bonforte, Valentina Forni-Ogna, Davide Giunzioni, Lorenzo Berwert, View ORCID ProfileRavindra K. Gupta, View ORCID ProfilePaolo Ferrari, View ORCID ProfileAlessandro Ceschi, View ORCID ProfilePietro Cippà, View ORCID ProfileDavide Corti, View ORCID ProfileAntonio Lanzavecchia, View ORCID ProfileLuca Piccoli
doi: https://doi.org/10.1101/2021.10.05.21264054
Jessica Bassi
1Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jessica Bassi
Olivier Giannini
2Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland
3Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Olivier Giannini
Chiara Silacci-Fregni
1Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Pertusini
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Hitz
2Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatiana Terrot
5Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yves Franzosi
5Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesco Muoio
1Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Saliba
1Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcel Meury
6Vir Biotechnology, San Francisco, California, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Exequiel A. Dellota Jr.
6Vir Biotechnology, San Francisco, California, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josh Dillen
6Vir Biotechnology, San Francisco, California, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Hernandez
6Vir Biotechnology, San Francisco, California, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadine Czudnochowski
6Vir Biotechnology, San Francisco, California, United States of America
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nadine Czudnochowski
Elisabetta Cameroni
1Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicola Beria
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariangela Ventresca
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alberto Badellino
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soraya Lavorato-Hadjeres
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisabetta Lecchi
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tecla Bonora
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matteo Mattiolo
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guido Trinci
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Garzoni
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Giuseppe Bonforte
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valentina Forni-Ogna
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Davide Giunzioni
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorenzo Berwert
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ravindra K. Gupta
7Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
8Department of Medicine, University of Cambridge, Cambridge, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ravindra K. Gupta
Paolo Ferrari
2Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
9Clinical School, University of New South Wales, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paolo Ferrari
Alessandro Ceschi
2Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland
5Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland
10Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Science of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland
11Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alessandro Ceschi
Pietro Cippà
3Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland
4Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland
12Faculty of Medicine, University of Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Pietro Cippà
Davide Corti
1Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Davide Corti
Antonio Lanzavecchia
1Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Antonio Lanzavecchia
Luca Piccoli
1Humabs Biomed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Luca Piccoli
  • For correspondence: lpiccoli@vir.bio
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Patients on dialysis are at risk of severe course of SARS-CoV-2 infection. Understanding the neutralizing activity and coverage of SARS-CoV-2 variants of vaccine-elicited antibodies is required to guide prophylactic and therapeutic COVID-19 interventions in this frail population. By analyzing plasma samples from 130 hemodialysis and 13 peritoneal dialysis patients after two doses of BNT162b2 or mRNA-1273 vaccines, we found that 35% of the patients had low-level or undetectable IgG antibodies to SARS-CoV-2 Spike (S). Neutralizing antibodies against the vaccine-matched SARS-CoV-2 and Delta variant were low or undetectable in 49% and 77% of patients, respectively, and were further reduced against other emerging variants. The fraction of non-responding patients was higher in SARS-CoV-2-naïve hemodialysis patients immunized with BNT162b2 (66%) than those immunized with mRNA-1273 (23%). The reduced neutralizing activity correlated with low antibody avidity. Patients followed up to 7 months after vaccination showed a rapid decay of the antibody response with an average 21- and 10-fold reduction of neutralizing antibodies to vaccine-matched SARS-CoV-2 and Delta variant, which increased the fraction of non-responders to 84% and 90%, respectively. These data indicate that dialysis patients should be prioritized for additional vaccination boosts. Nevertheless, their antibody response to SARS-CoV-2 must be continuously monitored to adopt the best prophylactic and therapeutic strategy.

Competing Interest Statement

J.B., C.S.-F., F.M., C.S., M.Me., E.A.D.J., N.C., E.C., D.C. A.L., and L.Pi. are employees of Vir Biotechnology Inc. and may hold shares in Vir Biotechnology Inc. R.K.G. has received consulting fees from Johnson and Johnson and GlaxoSmithKline for educational activities. The other authors declare no competing interests.

Funding Statement

The project was partially funded by the Swiss Kidney Foundation (to O.G.). R.K.G. received support from the G2P-UK National Virology consortium funded by MRC/UKRI (grant ref. MR/W005611/1).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Blood samples were obtained from 143 dialysis patients and 48 healthcare workers under study protocols approved by the local Institutional Review Boards (Canton Ticino Ethics Committee, Switzerland). Dialysis patients and HCW were recruited from the four public hospitals of the Ente Ospedaliero Cantonale (EOC) in Ticino (Southern Switzerland). All subjects provided written informed consent for the use of blood and blood components (such as PBMCs, sera or plasma).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • The revised version of the manuscript includes a new piece of follow-up data describing the decay of antibody titers in up to 7 months after the second COVID-19 mRNA-vaccine dose. The data are described in a new Results section and are accompanied by a new Figure 4 and supplementary S6 Fig. These findings are commented in the Discussion.

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 18, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients
Jessica Bassi, Olivier Giannini, Chiara Silacci-Fregni, Laura Pertusini, Paolo Hitz, Tatiana Terrot, Yves Franzosi, Francesco Muoio, Christian Saliba, Marcel Meury, Exequiel A. Dellota Jr., Josh Dillen, Patrick Hernandez, Nadine Czudnochowski, Elisabetta Cameroni, Nicola Beria, Mariangela Ventresca, Alberto Badellino, Soraya Lavorato-Hadjeres, Elisabetta Lecchi, Tecla Bonora, Matteo Mattiolo, Guido Trinci, Daniela Garzoni, Giuseppe Bonforte, Valentina Forni-Ogna, Davide Giunzioni, Lorenzo Berwert, Ravindra K. Gupta, Paolo Ferrari, Alessandro Ceschi, Pietro Cippà, Davide Corti, Antonio Lanzavecchia, Luca Piccoli
medRxiv 2021.10.05.21264054; doi: https://doi.org/10.1101/2021.10.05.21264054
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients
Jessica Bassi, Olivier Giannini, Chiara Silacci-Fregni, Laura Pertusini, Paolo Hitz, Tatiana Terrot, Yves Franzosi, Francesco Muoio, Christian Saliba, Marcel Meury, Exequiel A. Dellota Jr., Josh Dillen, Patrick Hernandez, Nadine Czudnochowski, Elisabetta Cameroni, Nicola Beria, Mariangela Ventresca, Alberto Badellino, Soraya Lavorato-Hadjeres, Elisabetta Lecchi, Tecla Bonora, Matteo Mattiolo, Guido Trinci, Daniela Garzoni, Giuseppe Bonforte, Valentina Forni-Ogna, Davide Giunzioni, Lorenzo Berwert, Ravindra K. Gupta, Paolo Ferrari, Alessandro Ceschi, Pietro Cippà, Davide Corti, Antonio Lanzavecchia, Luca Piccoli
medRxiv 2021.10.05.21264054; doi: https://doi.org/10.1101/2021.10.05.21264054

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Allergy and Immunology
Subject Areas
All Articles
  • Addiction Medicine (175)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (171)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8797)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1867)
  • Geriatric Medicine (179)
  • Health Economics (389)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (493)
  • Hematology (207)
  • HIV/AIDS (396)
  • Infectious Diseases (except HIV/AIDS) (10580)
  • Intensive Care and Critical Care Medicine (565)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1763)
  • Nursing (104)
  • Nutrition (267)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (966)
  • Ophthalmology (284)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (265)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (221)
  • Psychiatry and Clinical Psychology (1846)
  • Public and Global Health (3992)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (536)
  • Rheumatology (216)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (107)
  • Urology (80)